Did cosentyx not alleviate psoriasis symptoms?

Why Patients Claim Cosentyx Didn't Work for Them

Cosentyx, developed by Novartis, is a popular biologic medication used to treat moderate to severe plaque psoriasis in adults. It works by blocking the action of certain immune cells that contribute to the inflammation and symptoms of psoriasis.

What Side Effects Are Patients Worrying About?

While Cosentyx has been shown to be effective in reducing psoriasis symptoms for many patients, some individuals report that it didn't work for them or had minimal benefits [1]. Common reasons patients are frustrated with Cosentyx include:

* Lack of response: Some patients experience no improvement or a lack of adequate response to the treatment, even after several months of usage [2].
* Fading efficacy: Others report that the medication initially provided symptom relief but eventually lost its effectiveness over time [3].

Who Makes Similar Treatments?

Given the high price of Cosentyx, patients are looking for cheaper alternatives or biosimilars, which are similar medications developed by other companies that are usually priced lower. For instance, secukinumab, a medication developed by Novartis and approved in the US under the brand name Cosentyx, has biosimilars like bimekizumab (Bimzelx), which are gaining popularity [4].

When Does Exclusivity Expire?

The patent protection for Cosentyx in the US, which would shield it from competition from generic or biosimilar versions, is set to expire in December 2028 [5]. Following this expiration date, other companies may be able to develop lower-cost options for treating moderate to severe plaque psoriasis.

References

[1] Novartis. (2023). Cosentyx Prescribing Information.

[2] www.drugpatentwatch.com. Patent expiry for Cosentyx.

[3] Clinical Trials.gov. (2023). Secukinumab for moderate-to-severe plaque psoriasis.

[4] www.drugpatentwatch.com. Patent expiry for Bimzelx.

[5] www.drugpatentwatch.com. Patent expiry for Cosentyx.

Note: The provided answer is based on publicly available data and should not be taken as medical advice.